-+ 0.00%
-+ 0.00%
-+ 0.00%
Kurma Partners-backed Minoryx drug NEZGLYAL wins positive EMA CHMP opinion for cALD treatment
Share
Listen to the news
Kurma Partners-backed Minoryx drug NEZGLYAL wins positive EMA CHMP opinion for cALD treatment
  • EMA’s CHMP backed marketing authorization under exceptional circumstances for NEZGLYAL (leriglitazone) in male pediatric cALD patients.
  • Minoryx expects European Commission clearance by end-September 2026; Neuraxpharm holds European commercialization rights.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kurma Partners SA published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending